Related Experiment Videos
Subtype distribution among intravenous drug users with chronic type C hepatitis in southern Spain
1Department of Clinical Microbiology, University Hospital, Granada, Spain.
Insights
Hepatitis C virus (HCV) subtype 1a is emerging among young intravenous drug users (IVDU) in Southern Spain. This contrasts with subtype 1b, which is more prevalent in non-IVDU populations.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) infection remains a significant global health concern.
- Understanding HCV subtype distribution is crucial for effective treatment and prevention strategies.
- Intravenous drug users (IVDU) represent a key demographic for HCV transmission.
Purpose of the Study:
- To investigate the distribution of HCV subtypes in Southern Spain.
- To compare HCV subtype prevalence between intravenous drug users (IVDU) and non-IVDU patients.
- To assess the influence of HIV-1 coinfection on HCV subtype distribution in IVDU.
Main Methods:
- Genotyping was performed on 71 viraemic patients with chronic HCV.
- Patient groups included IVDU, HIV-1 coinfected individuals, and haemodialysis patients.
- Statistical analysis was used to correlate HCV subtypes with risk factors like IVDU and HIV-1 coinfection.
Main Results:
- HCV subtype 1a was significantly more prevalent in IVDU (48.5%) compared to non-IVDU (7.5%).
- HCV subtype 1b was significantly more prevalent in non-IVDU (85.1%) compared to IVDU (16.1%).
- No association was found between HIV-1 coinfection and HCV subtype distribution among IVDU.
Conclusions:
- HCV subtype 1a is emerging as the dominant strain among young IVDU in Southern Spain.
- HCV subtype distribution patterns differ significantly based on transmission risk factors, particularly IVDU.
- These findings highlight the need for targeted prevention and treatment approaches for specific populations.
Abstract:
The hepatitis C virus (HCV) subtype distribution among intravenous drug users (IVDU), and patients without this risk of acquiring HCV infection, was evaluated. The patients included in the study were 51 with chronic type C hepatitis (36 IVDU and 25 coinfected by HIV-1), and 31 on haemodialysis. Genotyping was performed on 71 viraemic patients, with the following distribution: 25.4%, 1a; 54.9%, 1b; 8.5%, 3a; 7%, mixed (1a, 1b; 3a, 1a; 3a, 1b; 2 x 3a, 2a); 1.4%, 4; and 2.8%, non-typeable. When subtypes were related to IVDU practice, the statistical significance was p < 0.01 for subtypes 1a (48.5% vs 7.5%, for IVDU and non-IVDU, respectively) and 1b (16.1% vs 85.1%). No relation between HIV-1 coinfection and subtype distribution was observed among IVDU patients. The results suggest that among young IVDU of Southern Spain the emerging HCV subtype is 1a.